Caio Max Rocha Lima to Infusions, Intravenous
This is a "connection" page, showing publications Caio Max Rocha Lima has written about Infusions, Intravenous.
Connection Strength
0.364
-
Rocha-Lima CM, de Queiroz Marques Junior E, Bayraktar S, Broome P, Weissman C, Nowacki M, Leslie M, Susnerwala S. A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan. Cancer Chemother Pharmacol. 2014 Sep; 74(3):479-86.
Score: 0.118
-
Lopes G, Quesada J, Ahn E, Flores A, Ribeiro A, Rocha-Lima CM. Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual. Clin Colorectal Cancer. 2007 Sep; 6(9):641-5.
Score: 0.073
-
Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004 Sep 15; 22(18):3776-83.
Score: 0.060
-
Rocha Lima CM, Catapano CV, Pacheco D, Sherman CA, Oakhill G, Mushtaq C, Freeman KD, Green MR. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors. Cancer. 2004 Jun 15; 100(12):2671-9.
Score: 0.059
-
Coutinho AK, Rocha Lima CM. Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control. 2003 May-Jun; 10(3):224-38.
Score: 0.054